Abivax SA Sponsored ADR (ABVX) AI Stock Analysis

• Market Cap: $9.86B
• Dividend Yield: N/A
• Average Volume (3M): 2.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.46
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.47
• Shares Outstanding: 78,444,145
• 10 Day Avg. Volume: 2,302,276
• 30 Day Avg. Volume: 1,998,233
• PEG Ratio: 0.14
• Price to Book (P/B): 10.98
• Price to Sales (P/S): 41.30
• P/FCF Ratio: -2.88
• Enterprise Value/Market Cap: 0.04
• Enterprise Value/Revenue: 46.22
• Enterprise Value/Gross Profit: 46.22
• Enterprise Value/Ebitda: -1.93
• 1Y Price Target: $153.88
• Price Target Upside: 23.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -3.49
• Revenue Forecast (FY): $5.72M

• Rating: 44 Neutral
• Price Target: $112.00 ▼(-10.41% Downside)

The score is primarily held down by weak financial performance—ongoing losses, negative operating cash flow, and reliance on financing with high leverage. Technicals offer only moderate support with a longer-term uptrend but weaker near-term momentum, while valuation lacks support due to negative earnings and no dividend yield.

Positive Factors

Proprietary immune‑modulating platform and lead asset

A proprietary immune‑modulating platform and a lead clinical asset (ABX464) targeting ulcerative colitis and Crohn’s provide durable product optionality. Platform breadth supports multiple indications, increasing chances of successful commercialization or partnering over the medium term.

Strong cash runway

A reported cash balance supporting runway into Q4 2027 materially reduces near‑term financing pressure, enabling continued clinical development and strategic optionality. This cash cushion supports multi‑stage trials and potential deal negotiations over the next 2–3 years.

Index inclusion increases structural investor base

Inclusion in the Nasdaq Biotechnology Index increases passive and institutional ownership potential, improving liquidity and visibility. That structural change tends to persist, supporting more stable investor demand and easier capital access for clinical-stage biotech firms.

Negative Factors

Persistent unprofitability and negative margins

Sustained negative EBIT and net margins indicate the business is not yet generating operating profits. Over the medium term this necessitates continued external funding or structural shifts to reach margin sustainability, making shareholder value creation dependent on trial success or licensing.

Negative operating cash flow and financing dependence

Negative operational cash flow combined with reliance on financing increases dilution and refinancing risk. This structural cash burn pattern forces management to prioritize funding rounds or deal‑making, which can constrain strategic flexibility and raise long‑term financing costs.

Rising R&D losses and financing‑related losses

Escalating R&D spend widening operating losses is typical in clinical biotech but, paired with financial losses from convertibles/warrants, it increases balance sheet strain and potential dilution. Over months this heightens funding needs and depresses return on equity until programs de‑risk.

Abivax SA Sponsored ADR Business Overview & Revenue Model

Company Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

How the Company Makes Money

Abivax SA generates revenue primarily through the development and eventual commercialization of its drug candidates. The company focuses on advancing its clinical trials to demonstrate the efficacy and safety of its products, which can lead to licensing agreements, partnerships, and potential acquisitions by larger pharmaceutical firms. Revenue streams may also include government grants, research and development collaborations, and milestone payments from partners upon achieving specific developmental or regulatory goals. Additionally, Abivax may benefit from equity financing and public offerings to fund its research initiatives.

Abivax SA Sponsored ADR Financial Statement Overview

Summary

Abivax SA faces significant financial challenges with consistent operational losses and reliance on debt financing. While revenue is growing, profitability remains a concern with high operating losses and negative cash flows. These factors underscore the need for strategic improvements to enhance financial stability.

Income Statement

The company has shown significant revenue growth from the previous year, but still operates at a loss with negative net profit and EBIT margins. The gross profit margin remains stable, yet the high negative EBIT and net income suggest ongoing operational challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a substantial debt-to-equity ratio, but it has managed to maintain a reasonable equity ratio. The return on equity remains negative due to continued losses, suggesting difficulty in generating shareholder value.

Cash Flow

Cash flow from operations is negative, reflecting operational struggles, although there is positive free cash flow growth due to reduced capital expenditures. The company relies heavily on financing activities to manage its cash needs, indicating potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.42M	10.79M	4.62M	4.58M	37.00K	63.00K
Gross Profit	9.42M	10.79M	4.57M	4.47M	-119.00K	-33.77M
EBITDA	-225.56M	-171.88M	-133.21M	-53.31M	-38.59M	-38.00M
Net Income	-195.39M	-176.24M	-147.74M	-60.74M	-42.45M	-37.55M
Balance Sheet
Total Assets	119.64M	205.23M	327.06M	75.54M	109.23M	71.30M
Cash, Cash Equivalents and Short-Term Investments	60.95M	144.22M	260.99M	26.95M	60.70M	29.30M
Total Debt	84.57M	97.36M	58.04M	39.16M	51.65M	33.99M
Total Liabilities	167.92M	164.64M	131.05M	68.36M	83.30M	53.40M
Stockholders Equity	-48.28M	40.58M	196.01M	7.19M	25.93M	17.90M
Cash Flow
Free Cash Flow	-135.98M	-154.72M	-100.28M	-54.26M	-47.30M	-30.72M
Operating Cash Flow	-135.51M	-154.07M	-100.01M	-53.94M	-45.66M	-29.82M
Investing Cash Flow	2.42M	15.76M	-10.49M	-12.03M	-1.46M	-575.00K
Financing Cash Flow	-20.88M	28.21M	340.57M	32.21M	78.51M	49.93M

Abivax SA Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 125.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Positive. The current price of 125.01 is below the 20-day moving average (MA) of 126.19, above the 50-day MA of 119.20, and above the 200-day MA of 62.06, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 51.58 is Neutral, neither overbought nor oversold. The STOCH value of 39.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVX.

Abivax SA Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RNA	62 Neutral	$10.94B	―	-32.44%	―	106.27%	-43.90%
CYTK	57 Neutral	$7.90B	-10.24	―	―	2609.26%	-17.08%
NUVL	54 Neutral	$7.84B	-20.29	-38.79%	―	―	-52.84%
RYTM	53 Neutral	$7.56B	-36.52	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	46 Neutral	$4.30B	-17.83	-22.60%	―	74.91%	31.54%
ABVX	44 Neutral	$9.86B	-41.34	―	―	―	18.47%

Abivax SA Sponsored ADR Corporate Events

Abivax SA Reports Increased Losses in Q3 2025 Amid Rising R&D Costs

On December 15, 2025, Abivax SA announced its financial results for the third quarter of 2025, highlighting a significant increase in operating loss due to rising research and development expenses, particularly in its ulcerative colitis and Crohn’s disease programs. Despite a decrease in sales and marketing expenses, the company’s net loss widened due to increased personnel costs and financial losses related to convertible notes and warrants. Abivax’s cash position remains strong, with cash and cash equivalents of EUR 589.7 million, providing a runway into the fourth quarter of 2027.

The most recent analyst rating on (ABVX) stock is a Buy with a $142.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.